Compare INOD & WGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | INOD | WGS |
|---|---|---|
| Founded | 1988 | 2017 |
| Country | United States | United States |
| Employees | 3000 | N/A |
| Industry | EDP Services | Retail: Computer Software & Peripheral Equipment |
| Sector | Technology | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.7B |
| IPO Year | 1996 | 2020 |
| Metric | INOD | WGS |
|---|---|---|
| Price | $42.94 | $69.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | ★ $122.75 | $93.50 |
| AVG Volume (30 Days) | ★ 1.5M | 722.5K |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 3.37 | ★ 62.37 |
| EPS | ★ 0.86 | N/A |
| Revenue | $86,775,000.00 | ★ $427,539,000.00 |
| Revenue This Year | $42.87 | $12.70 |
| Revenue Next Year | $27.95 | $24.31 |
| P/E Ratio | $53.27 | ★ N/A |
| Revenue Growth | 9.84 | ★ 39.97 |
| 52 Week Low | $34.23 | $32.21 |
| 52 Week High | $125.14 | $170.87 |
| Indicator | INOD | WGS |
|---|---|---|
| Relative Strength Index (RSI) | 33.00 | 48.91 |
| Support Level | $40.89 | $68.55 |
| Resistance Level | $47.79 | $73.04 |
| Average True Range (ATR) | 3.75 | 5.62 |
| MACD | -1.58 | 0.96 |
| Stochastic Oscillator | 2.82 | 81.47 |
Innodata Inc is a data engineering company. It is helping companies deploy and integrate AI into their operations and products and providing AI-enabled industry platforms. The Company's operations are classified in three reporting segments: Digital Data Solutions (DDS), Synodex and Agility. Key revenue is generated from DDS segment provides AI data preparation services, collecting or creating training data, annotating training data, and training AI algorithms for its customers, and AI model deployment and integration. It also provides a range of data engineering support services including data transformation, data curation, data hygiene, data consolidation, data extraction, data compliance, and master data management.
GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.